February 20 – 23, 2018
Taj Diplomatic Enclave
New Delhi, India
Organized by DR-TB STAT
The symposium will provide an update on the UNITAID-funded endTB initiative and findings, including culture conversion and reversion and adverse events for the 600 people who have received bedaquiline or delamanid.
Evidence for treatment with newer DR-TB drugs, shorter treatment regimens, ambulatory care instead of hospitisation, and fast-track registration of new drugs.
Session will analyse the barriers to reducing costs and burden for people with drug-resistant TB including: decentralised and ambulatory treater, shorter treatment and newer drugs to reduce toxicity, and interventions to reduce out-of-pocket costs of treatment.
U.S. Centers for Disease Control and Prevention (CDC), The United Nations Children’s Fund (UNICEF), and Child Survival Working Group
The webinar will be moderated by Anne Detjen, UNICEF, Surbhi Modi, CDC and Jessica Rodrigues, UNICEF.
1) TB in women, infants, children and adolescents – key data, gaps and opportunities
Steve Graham, University of Melbourne and The International Union Against TB and Lung Disease
2) Addressing TB along the lifecycle – lessons from Uganda
Moorine Sekadde, National TB Programme, Uganda
3) Kenya’s experience providing IPT in PMTCT settings
Immaculate Kathure, National TB Programme, Kenya
Use Conference ID: 57813351
Organized by Treatment Action Group (TAG)
Tuberculosis (TB) is the leading killer of people living with HIV, making the TB LAM test critically important to saving the lives of people living with HIV. LAM is the only point-of-care TB diagnostic test, and is specifically used for detecting TB in people with HIV with low CD4 counts. The LAM test is the only test that has a proven impact on reducing TB deaths in people with HIV.
Join TAG and global partners for a webinar on urging policymakers and funders to procure and implement the TB LAM test.
1) Lynette Mabote AIDS & Rights Alliance for Southern Africa
2) Stephen Wanjala, Médecins Sans Frontières Wayne van Gemert,
3) Global Drug Facility
Moderator: Khairunisa Suleiman, Global TB CAB and Independent Consultant